Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?

Everett BM.

J Am Coll Cardiol. 2017 Feb 7;69(5):483-485. doi: 10.1016/j.jacc.2016.11.036. No abstract available.

PMID:
28153103
2.

Biomarkers for Cardiovascular Screening: Progress or Passé?

Everett BM, Ridker PM.

Clin Chem. 2017 Jan;63(1):248-251. doi: 10.1373/clinchem.2016.254854. Epub 2016 Nov 30. No abstract available.

PMID:
27903617
3.

Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death.

Everett BM, Hiatt WR.

Circulation. 2016 Sep 6;134(10):773-5. doi: 10.1161/CIRCULATIONAHA.116.024512. Review. No abstract available.

PMID:
27601559
4.

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.

Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, Pennells L, Gao P, Burgess S, Freitag DF, Sweeting M, Wood AM, Cook NR, Judd S, Trompet S, Nambi V, Olsen MH, Everett BM, Kee F, Ärnlöv J, Salomaa V, Levy D, Kauhanen J, Laukkanen JA, Kavousi M, Ninomiya T, Casas JP, Daniels LB, Lind L, Kistorp CN, Rosenberg J, Mueller T, Rubattu S, Panagiotakos DB, Franco OH, de Lemos JA, Luchner A, Kizer JR, Kiechl S, Salonen JT, Goya Wannamethee S, de Boer RA, Nordestgaard BG, Andersson J, Jørgensen T, Melander O, Ballantyne ChM, DeFilippi Ch, Ridker PM, Cushman M, Rosamond WD, Thompson SG, Gudnason V, Sattar N, Danesh J, Di Angelantonio E.

Lancet Diabetes Endocrinol. 2016 Oct;4(10):840-9. doi: 10.1016/S2213-8587(16)30196-6. Epub 2016 Sep 3.

5.

Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group..

J Am Coll Cardiol. 2016 Aug 30;68(9):978-80. doi: 10.1016/j.jacc.2016.06.013. No abstract available.

PMID:
27561773
6.

Assessing the Effects of Diet and Behavior on Cardiovascular Disease: The Role of Biomarkers in Understanding Biology and Mechanism.

Lawler PR, Everett BM.

Clin Chem. 2016 Sep;62(9):1169-71. doi: 10.1373/clinchem.2016.260448. Epub 2016 Jul 18. No abstract available.

PMID:
27430707
7.

Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations.

Everett BM.

Trends Cardiovasc Med. 2017 Jan;27(1):41-47. doi: 10.1016/j.tcm.2016.06.002. Epub 2016 Jun 10. Review.

PMID:
27422097
8.

Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women.

Jiménez MC, Rexrode KM, Kotler G, Everett BM, Glynn RJ, Lee IM, Buring JE, Ridker PM, Sesso HD.

Am J Hypertens. 2016 Sep;29(9):1117-24. doi: 10.1093/ajh/hpw050. Epub 2016 May 28.

PMID:
27235695
9.

Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium.

Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ, Jørgensen T, Thorand B, Peters A, Nauck M, Petersmann A, Vartiainen E, Veronesi G, Brambilla P, Costanzo S, Iacoviello L, Linden G, Yarnell J, Patterson CC, Everett BM, Ridker PM, Kontto J, Schnabel RB, Koenig W, Kee F, Zeller T, Kuulasmaa K; BiomarCaRE Investigators..

Eur Heart J. 2016 Aug 7;37(30):2428-37. doi: 10.1093/eurheartj/ehw172. Epub 2016 May 12.

10.

Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.

Patorno E, Everett BM, Goldfine AB, Glynn RJ, Liu J, Gopalakrishnan C, Kim SC.

Diabetes Obes Metab. 2016 Aug;18(8):755-65. doi: 10.1111/dom.12665. Epub 2016 May 2.

PMID:
27003762
11.

Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations.

Srivastava PK, Pradhan AD, Cook NR, Ridker PM, Everett BM.

Am J Cardiol. 2016 Feb 1;117(3):376-81. doi: 10.1016/j.amjcard.2015.10.054. Epub 2015 Nov 18.

12.

Troponin in Stable Ischemic Heart Disease and Diabetes.

Everett BM, Brooks MM, Bhatt DL.

N Engl J Med. 2015 Nov 12;373(20):1978-9. doi: 10.1056/NEJMc1511645. No abstract available.

13.

Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Everett BM, Smith RJ, Hiatt WR.

N Engl J Med. 2015 Oct 22;373(17):1588-91. doi: 10.1056/NEJMp1508120. Epub 2015 Oct 7. No abstract available.

14.

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group..

N Engl J Med. 2015 Aug 13;373(7):610-20. doi: 10.1056/NEJMoa1415921.

15.

Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study).

Everett BM, Ridker PM, Cook NR, Pradhan AD.

Am J Cardiol. 2015 Aug 15;116(4):532-7. doi: 10.1016/j.amjcard.2015.05.014. Epub 2015 May 21.

16.

High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy.

Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S.

Circulation. 2015 May 26;131(21):1851-60. doi: 10.1161/CIRCULATIONAHA.114.014522. Epub 2015 Mar 30.

17.

Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease.

Taqueti VR, Everett BM, Murthy VL, Gaber M, Foster CR, Hainer J, Blankstein R, Dorbala S, Di Carli MF.

Circulation. 2015 Feb 10;131(6):528-35. doi: 10.1161/CIRCULATIONAHA.114.009716. Epub 2014 Dec 5.

18.

B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women.

Everett BM, Berger JS, Manson JE, Ridker PM, Cook NR.

J Am Coll Cardiol. 2014 Oct 28;64(17):1789-97. doi: 10.1016/j.jacc.2014.04.089. Epub 2014 Oct 21.

19.

Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).

Everett BM, Mora S, Glynn RJ, MacFadyen J, Ridker PM.

Am J Cardiol. 2014 Dec 1;114(11):1682-9. doi: 10.1016/j.amjcard.2014.08.041. Epub 2014 Sep 16.

PMID:
25439449
20.

Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)".

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S.

Circulation. 2014 Oct 21;130(17):e152. doi: 10.1161/CIRCULATIONAHA.114.010927. No abstract available.

Supplemental Content

Loading ...
Support Center